Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 10, 2004, Pages 2551-2554

  Chen, Helen Y ^a   Kim, Seongkon ^a   Wu, Jane Y ^a   Birzin, Elizabeth T ^a   Chan, Wanda ^a   Yang, Yi Tien ^a   Dahllund, Johanna ^b   DiNinno, Frank ^a   Rohrer, Susan P ^a   Schaeffer, James M ^a   Hammond, Milton L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Karo Bio   (Sweden)

Author keywords

Dihydrobenzoxathiin; SERAMs; SERMs

Indexed keywords

ANTIESTROGEN; DIHYDROBENZOXATHIIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LIGAND; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; ESTROGEN ACTIVITY; IN VITRO STUDY; IN VIVO CULTURE; STRUCTURE ACTIVITY RELATION; UTERUS;

ANIMALS; CELL LINE; CELL PROLIFERATION; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; ORGAN SIZE; RATS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; UTERUS;

EID: 11144354858     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.02.084     Document Type: Article

References (23)

1. Lindsay R. Riggs B.L., Melton L.J. Osteoporosis: Etiology, Diagnosis, and Management. 1988;333 Raven, New York.
2. Ross R.K., Pike M.C., Mack T.M., Henderson B.E. Drife J.O., Studd J.W.W. HRT and Osteoporosis. 1990;209 Springer, London.
3. Manson J.E., Martin K.A. N. Engl. J. Med. 345:2001;34.
4. Keating N.L., Cleary P.D., Rossi A.S., Zaslavsky A.M., Ayanian J.Z. Ann. Int. Med. 130:1999;545.
5. Kooistra T., Emeis J. J. Curr. Opin. Chem. Biol. 3:1999;495.
6. Recent reviews on SERMs: Jordan V.C. J. Med. Chem. 46:2003;883.
7. Jordan V.C. J. Med. Chem. 46:2003;1081.
8. Meegan M.J., Lloyd D.G. Curr. Med. Chem. 10:2003;181.
9. Miller C.P. Curr. Pharm. Des. 8:2002;2089.
10. Bryant H.U. Endocr. Metab. Disorders. 3:2002;231.
11. Grese T.A., Pennington L.D., Sluka J.P., Adrian M.D., Cole H.W., Fuson T.R., Magee D.E., Phillips D.L., Rowley E.R., Shetler P.K., Short L.L., Venugopalan M., Yang N.N., Sato M., Glasebrook A.L., Bryant H.U. J. Med. Chem. 41:1998;1272.
12. Jordan V.C. Br. J. Pharmacol. 110:1993;507.
13. Kim, S.; Wu Jane, Y.; Birzin, E.; Frisch, K.; Chan, W.; Pai, L.; Yang, Y.; Mosley, R. T.; Fitzgerald, P.; DiNinno, F.; Rohrer, S. P.; Schaeffer, J. M.; Hammond, M. L. J. Med. Chem., in press
14. Kim S., Wu J.Y., Chen H.Y., DiNinno F. Org. Lett. 5:2003;685-688.
15. Ganesh T., Kumar H., Krupadanam G.L. Synth. Commun. 29:1999;2069. and references cited therein.
16. (b) The thiophenols 3 were prepared by known procedures with minor modifications: Werner, G.; Biebrich, W. U.S. Patent 2,276,553; 2,332,418
17. Hanzlik R.P., Weller P.E., Desai J., Zheng J., Hall L.R., Slaughter D.E. J. Org. Chem. 55:1990;2736.
18. The lithium anions of 3- and 4-picoline were prepared according to previously reported method: Koller M.U., Peariso K.L., Guion T., Martinez S.S., Beam C.F. Synth. Commun. 25:1995;2963-2974.
19. Aicart M., Mavoungou-Gomes L. J. Heterocycl. Chem. 22:1985;921-925.
20. Ascoli R.D., D'Auria M., Piancatelli G., Scettri A. Tetrahedron. 35:1979;2905-2907.
21. 50 values were generated in an estrogen receptor ligand binding assay. This scintillation proximity assay was conducted in NEN Basic Flashplates using tritiated estradiol and full length recombinant human ERα and ERβ proteins with a 3 h incubation time. Most compounds are single point determinants unless otherwise indicated by standard deviation where n =2-5.
22. ′-chloro)tricyclo[3.3.1.13,7] decan}-4-yl)phenyl phosphate] in white 96 well plates and product formation was measured using a microplate luminometer. An integral measurement with 1-s reading of each well was used. ALP activity was expressed in light units (LU), which was directly proportional to the level of ALP expression from the cells.
23. Twenty-day old intact Sprague-Dawley rats were treated (sc) with test compounds for 3 days at 1 mpk. The anti-estrogenic activity of compounds was determined by co-administration of the compound with a subcutaneous injection of 17-β-estradiol and reported as % inhibition. The estrogenic activity (partial agonism) of the compounds was determined by administering the test compound without estradiol and reported as % control.